secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001104659-24-060195
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee reports Q1 net loss $32.1M, cash $816M, advances pipeline with Phase 2 start for APG777 and $483M raise
--------------------------------------------------------------------------------

- Net loss $32.1M vs $12.5M YoY; R&D expenses $28.7M (up from $8.5M) as pipeline progresses.
- Cash, equivalents and marketable securities $816.2M; runway into early 2028.
- Completed upsized public offering raising $483M gross proceeds at $62.00/share.
- Initiated Phase 2 trial of APG777 (IL-13) in atopic dermatitis; proof-of-concept data expected 2H 2025.
- Dosed first participant in Phase 1 trial of APG808 (IL-4Rα); interim data expected 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000110465924060195/0001104659-24-060195-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000110465924060195/tm2414075d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-060195

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer